Malibu, CA, Sep 18, 2023 AEST (ABN Newswire) - Join Ellis Martin for a compelling interview with Dr. Seth Lederman. He's an MD and the CEO of TONIX Pharmaceuticals Holding Corp. (NASDAQ:TNXP). Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. The company is currently developing medicines to treat conditions including long covid, fibromyalgia, lupus, organ transplant rejection, depression, autism, MS, chronic pain. PTSD, migraines, cocaine intoxication, gastro-intestinal cancer and more.
Dr. Lederman is a physician, scientist and entrepreneur, and the founder of Tonix. Prior to Tonix, Dr. Lederman founded Targent Pharmaceuticals, which developed late-stage oncology drugs.
Prior to becoming a biopharma entrepreneur, Dr. Lederman served as an Associate Professor at Columbia University for 2 decades and directed basic science research in molecular immunology, infectious diseases and the development of therapeutics for autoimmune disease.
TONIX Pharmaceuticals is a paid sponsor of The Ellis Martin Report
To Listen to the Interview, please visit:
About The Ellis Martin Report
The Ellis Martin Report (TEMR) is an internet based radio program showcasing potentially undervalued companies to an audience of potential retail investors and fund managers that comprise our listening audience. TEMR is broadcasted on the VoiceAmerica Business Channel and The Opportunity Radio Network. CEO and company interviews are paid for by those represented on the program.
About TONIX Pharmaceuticals Holdings Corp.
TONIX Pharmaceuticals Holdings Corp. (NASDAQ:TNXP) is a biopharmaceutical company focused on bringing novel therapeutics and diagnostics to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases.
At Tonix, we are focused on identifying and developing candidates that have the promise to treat and prevent human disease and alleviate suffering. Through our own development, in-licensing, collaborations and acquisitions we are curating an innovative and effective portfolio that targets the relief of pain and attenuates infection. Currently, our pipeline is primarily comprised of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix's immunology portfolio includes biologics to address organ transplant rejection, auto-immunity, and cancer. Our infectious disease portfolio includes a live virus vaccine platform, and a potential treatment for Long COVID. We are progressing small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions through our CNS portfolio.
TONIX Pharmaceuticals Holdings Corp.
The Ellis Martin Report